Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €245.47 EUR
Change Today -1.21 / -0.49%
Volume 1.9K
RHO On Other Exchanges
Symbol
Exchange
OTC US
Xetra
SIX Swiss Ex
Xetra
SIX Swiss Ex
Frankfurt
As of 1:36 PM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-br (RHO) Snapshot

Open
€246.00
Previous Close
€246.68
Day High
€247.60
Day Low
€244.20
52 Week High
06/1/15 - €270.00
52 Week Low
10/13/14 - €201.00
Market Cap
217.5B
Average Volume 10 Days
3.2K
EPS TTM
--
Shares Outstanding
160.0M
EX-Date
03/5/15
P/E TM
--
Dividend
€7.78
Dividend Yield
3.04%
Current Stock Chart for ROCHE HOLDING AG-BR (RHO)

roche holding ag-br (RHO) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Europe, North America, and Asia. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, drug metabolism disorder, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, human papillomavirus, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and west nile virus diseases. The company also provides diagnostic solutions for blood gas analysis; blood screening; cancer screening; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring, routing, and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogenous immune assays; immunology; infectious diseases; intensive care testing; microarray; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; pharmacogenomics; physical fitness and platelet function testing; PCR diagnostic systems; serum work area; urinalysis; and workflow solutions. In addition, it offers products for researchers, such as amplification, cell analysis, gene expression, gene knockdown, genome sequencing, microarrays, nucleic acid purification, protein analysis, PCR systems, and transfection products. The company has collaboration agreements with AmorChem, AbbVie, Xenon Pharmaceuticals, Stratos Genomics, The Garvan Institute, Cornell University, and University of Washington. The company was founded in 1896 and is headquartered in Basel, Switzerland.

88,509 Employees
Last Reported Date: 01/28/15
Founded in 1896

roche holding ag-br (RHO) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.3M
Chief Financial Officer and IT Officer
Total Annual Compensation: SFr.4.1M
Chief Operating Officer of Pharmaceuticals di...
Total Annual Compensation: SFr.5.0M
Chief Operating Officer of Diagnostics Divisi...
Total Annual Compensation: SFr.2.5M
General Counsel and Corporate Secretary
Total Annual Compensation: SFr.2.8M
Compensation as of Fiscal Year 2014.

roche holding ag-br (RHO) Key Developments

Roche Announces Positive Results from Two Pivotal Studies Evaluating the Investigational Medicine ocrelizumab Compared with interferon beta-1a (Rebif)

Roche announced positive results from two pivotal studies evaluating the investigational medicine ocrelizumab compared with interferon beta-1a (Rebif), a standard-of-care therapy, in people with relapsing multiple sclerosis (MS), the most common form of the disease. The studies (called OPERA I and OPERA II) met their primary and major secondary endpoints. Treatment with ocrelizumab significantly reduced the annualised relapse rate (ARR) over a two-year period compared with interferon beta-1a, the primary endpoint in both studies. Ocrelizumab also significantly reduced the progression of clinical disability compared with interferon beta-1a, as measured by the Expanded Disability Status Scale (EDSS). Additionally, treatment with ocrelizumab led to a significant reduction in the number of lesions in the brain (areas of disease activity) compared with interferon beta-1a, as measured by MRI. Overall, the incidence of adverse events associated with ocrelizumab was similar to interferon beta-1a in both studies; the most common adverse events were mild-to-moderate infusion-related reactions. The incidence of serious adverse events associated with ocrelizumab, including serious infections, was also similar to interferon beta-1a. Further analyses of the OPERA studies are ongoing and detailed data will be presented at an upcoming medical congress. Results from a Phase III study of ocrelizumab in people with primary progressive MS (PPMS), a different form of MS, are expected later 2015.

Roche's Ocrelizumab Reduces Both Relapses and Disability Progression Versus Interferon Beta-1A (Rebif(Registered)) in Two Phase III Studies in Multiple Sclerosis

Roche announced positive results from two pivotal studies evaluating the investigational medicine ocrelizumab compared with interferon beta-1a (Rebif(Registered)), a standard-of-care therapy, in people with relapsing multiple sclerosis (MS), the most common form of the disease. The studies (called OPERA I and OPERA II) met their primary and major secondary endpoints. Treatment with ocrelizumab significantly reduced the annualised relapse rate (ARR) over a two-year period compared with interferon beta-1a, the primary endpoint in both studies. Ocrelizumab also significantly reduced the progression of clinical disability compared with interferon beta-1a, as measured by the Expanded Disability Status Scale (EDSS). Additionally, treatment with ocrelizumab led to a significant reduction in the number of lesions in the brain (areas of disease activity) compared with interferon beta-1a, as measured by MRI. Overall, the incidence of adverse events associated with ocrelizumab was similar to interferon beta-1a in both studies; the most common adverse events were mild-to-moderate infusion-related reactions. The incidence of serious adverse events associated with ocrelizumab, including serious infections, was also similar to interferon beta-1a. OPERA I and OPERA II are Phase III, randomised, double-blind, double-dummy, global multi-centre studies evaluating the efficacy and safety of ocrelizumab (600 mg dose administered by intravenous infusion every 6 months) compared with interferon beta-1a (44 mcg dose administered by subcutaneous injection three times per week) in people with relapsing forms of MS.1 The primary endpoint of the OPERA studies was annualised protocol-defined relapse rate (ARR) at two years (96 weeks). Secondary endpoints included time to onset of confirmed disability progression, the total number of T1 Gadolinium-enhancing lesions, and total number of new and/or enlarging T2 hyperintense lesions as detected by brain MRI. The OPERA I and OPERA II studies enrolled a total of 1,656 people with relapsing forms of MS (that is, relapsing-remitting MS and secondary-progressive MS with relapses) across 307 sites in 40 countries.

Evotec’s Partner Roche Provides Initial Update from Phase IIb Trial in Alzheimer’s Disease

Evotec AG was updated by its partner Roche on the initial results of the Phase IIb trial with Sembragiline (RG1577, EVT302), a MAO-B inhibitor for the treatment of Alzheimer’s disease (AD). In this study, Sembragiline failed to demonstrate benefit on the primary endpoint (Alzheimer’s Disease Assessment Scale – Cognitive Behaviour Subscale, ADAS-cog-11) after 52 weeks of treatment. Preliminary safety analyses showed that Sembragiline was well tolerated with no safety signals identified. Roche has initiated a process to evaluate all secondary endpoint read-outs on Sembragiline and to consider all further development options. The multicentre, randomised, double-blind, parallel-group, placebo-controlled Phase IIb study was undertaken to evaluate the efficacy and safety of Sembragiline in patients with moderate severity Alzheimer’s disease added on background of AD standard therapy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHO:GR €245.47 EUR -1.21

RHO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $115.04 USD -0.97
Merck & Co Inc $57.67 USD +0.07
Novartis AG SFr.93.05 CHF -0.85
Pfizer Inc $33.37 USD -0.32
Sanofi €88.18 EUR -0.90
View Industry Companies
 

Industry Analysis

RHO

Industry Average

Valuation RHO Industry Range
Price/Earnings 25.5x
Price/Sales 4.7x
Price/Book 12.0x
Price/Cash Flow 20.8x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-BR, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.